Trials / Not Yet Recruiting
Not Yet RecruitingNCT07456033
A Study of Efficacy and Safety of Depemokimab Compared With Placebo in Adults and Adolescents With at Risk Type 2 Asthma
The MODIFY Study: A Phase 3b/4 Randomized, Double-blind, Placebo-controlled, Multi-centre Study Evaluating the Impact of Early Intervention With Depemokimab on Exacerbation Rate, Clinical Remission, Lung Function Decline, and Safety in Adults and Adolescents With at Risk Type 2 Asthma, Conducted up to 156 Weeks
- Status
- Not Yet Recruiting
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 456 (estimated)
- Sponsor
- GlaxoSmithKline · Industry
- Sex
- All
- Age
- 12 Years
- Healthy volunteers
- Not accepted
Summary
The aim of this study is to evaluate the efficacy of depemokimab administered as an adjunctive therapy, in participants with Type 2 asthma at risk of exacerbations compared to the guideline recommended standard of care (SoC).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Depemokimab | Depemokimab will be administered |
| DRUG | Placebo | Placebo will be administered |
Timeline
- Start date
- 2026-03-06
- Primary completion
- 2030-07-01
- Completion
- 2030-07-01
- First posted
- 2026-03-06
- Last updated
- 2026-03-06
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT07456033. Inclusion in this directory is not an endorsement.